环胞素A硬脂酸毫微球防治实验性增殖性玻璃体视网膜病变  

Biodegradable nanoparticles containing Cyclosporine A in the treatment of proliferative vitreoretinopathy

作　　者：刘瑜玲[1] 陈改清[2] 张强[3] 徐亮[1] 张士元[1] 

机构地区：[1]北京市眼科研究所,100005 [2]首都医科大学化学教研室 [3]北京医科大学药学院

出　　处：《中国实用眼科杂志》1999年第9期527-530,共4页Chinese Journal of Practical Ophthalmology

基　　金：北京市教委科技发展基金

摘　　要：评价生物降解性的环胞素 Ａ 硬脂酸毫微球对兔眼实验性增殖性玻璃体视网膜病变的防治作用。方法： 成年健康灰兔 ３０ 只， 随机分组， 对照组 ２０ 只眼内注入 １％ 空白毫微球悬液或磷酸缓冲液 （ Ｐ Ｂ Ｓ）； 环胞素 Ａ 毫微球组 （含环胞素 Ａ０８ｍ ｇ／ｍ ｌ或 １６ｍ ｇ／ｍ ｌ， ２ 组各２０ 只眼）。各组均先后２ 次行气体压迫玻璃体手术。第二次玻璃体注气后第 ７ 天， 所有实验眼玻璃体腔内注入成纤维细胞悬液 ２×１０５ ／０１ｍ ｌ， 再分别注入空白毫微球， Ｐ Ｂ Ｓ或载药毫微球悬液 ０１ｍ ｌ。以间接检眼镜观察牵引性视网膜脱离发生情况， 共四周。结果： ４ 周末时对照组、环胞素 Ａ 毫微球 ０８ｍ ｇ／ｍ ｌ组、环胞素 Ａ 毫微球 １６ｍ ｇ／ｍ ｌ组的牵引性视网膜脱离的发生率分别为 ９０％ 、５２６％ 和３０％ ， 两个环胞素 Ａ 毫微球组与对照组相比经统计学处理有显著性差异 （ Ｐ＜ ００１）。结论： 一次性注入环胞素 Ａ 生物降解性毫微球能够有效地减少牵引性视网膜脱离的发生率。To evaluate the possibility of biodegradable cyclosporine A stearic acid nanoparticles (CyA SA NP) for the treatment of proliferative vitreoretinopathy(PVR)in an experimental rabbit model.Methods:Thirty pigmented rabbits (59 eyes) were divided into three groups.The nanoparticles without drug(10 eyes) and phosphate buffer solution(PBS)(10 eyes)were injected intravitreally as the control.The CyA SA NP containing 0 8mg/ml (19 eyes) or 1 6mg/ml(20 eyes) of CyA were injected into other two groups respectively.Seven days after second gas compression vitrectomy,2×10 5 fibroblastes and CyA SA NP(or control)were injected in all eyes sequentially.The morbidity of tractional retinal detachment (TRD) were observed by ophthalmoscope for 4 weeks.Results:4 weeks later,the morbidity of TRD in control,0.8mg/ml and 1.6mg/ml CyA SA NP group was 90%,52 6%,and 30% respectively.Significant statistical differences were found between the control group and the two treated groups (P<0 01).Conclusions:The CyA SA NP containing 0 8mg/ml or 1 6mg/ml of CyA can inhibit the occurrence of TRD effectively.

关 键 词：毫微球 环孢素A 增殖性 玻璃体 视网膜病变 

分 类 号：R774.120.5[医药卫生—眼科]